JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Secretion and Expression of Matrix Metalloproteinase-2 and 9 from Bone Marrow Mononuclear Cells in Myelodysplastic Syndrome and Acute Myeloid Leukemia
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Secretion and Expression of Matrix Metalloproteinase-2 and 9 from Bone Marrow Mononuclear Cells in Myelodysplastic Syndrome and Acute Myeloid Leukemia
Chaudhary, Ajay K; Chaudhary, Shruti; Ghosh, Kanjaksha; Shanmukaiah, Chandrakala; Nadkarni, Anita H;
  PDF(new window)
 Abstract
Background: Matrix metalloproteinase -2 (gelatinase-A, Mr 72,000 type IV collagenase, MMP-2) and -9 (gelatinase-B, Mr 92,000 type IV collagenase, MMP-9) are key molecules that play roles in tumor growth, invasion, tissue remodeling, metastasis and stem-cell regulation by digesting extracellular matrix barriers. MMP-2 and -9 are well known to impact on solid cancer susceptibility, whereas, in hematological malignancies, a paucity of data is available to resolve the function of these regulatory molecules in bone marrow mononuclear cells (BM-MNCs) and stromal cells of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Objectives: The present study aimed to investigate mRNA expression and gelatinase A and B secretion from BM-MNCs in vitro and genotypic associations of MMP-2 (-1306 C/T; rs243865), MMP-9 (-1562 C/T; rs3918242), tissue inhibitor of metalloproteinase -1 (TIMP-1) (372T/C; rs4898, Exon 5) and TIMP-2 (-418G/C; rs8179090) in MDS and AML. Results: The study covered cases of confirmed MDS (n
 Keywords
MMP-2 and 9 polymorphisms;mRNA expression;myelodysplastic syndrome;acute myeloid leukemia;
 Language
English
 Cited by
1.
miRNA-301a induces apoptosis of chronic myelogenous leukemia cells by directly targeting TIMP2/ERK1/2 and AKT pathways, Oncology Reports, 2016, 37, 2, 945  crossref(new windwow)
 References
1.
Barille S, Akhoundi C, Collette M, et al (1997). Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells. Blood, 90, 1649-55.

2.
Chang YC, Yang SF, Tai KW, et al (2002). Increased tissue inhibitor of metalloproteinase-1 expression and inhibition of gelatinase A activity in buccal mucosal fibroblasts by arecoline as possible mechanisms for oral submucous fibrosis. Oral Oncol, 38, 195-200. crossref(new window)

3.
Chaubey R, Sazawal S, Dada R, et al (2011). Cytogenetic profile of Indian patients with de novo myelodysplastic syndromes. Indian J Med Res, 134, 452-7.

4.
Chaudhary AK, Pandya S, Ghosh K, et al (2013). Matrix metalloproteinase and its drug targets therapy in solid and hematological malignancies: an overview. Mutat Res, 753, 7-23. crossref(new window)

5.
Chaudhary AK, Pandya S, Mehrotra R, et al (2010a). Functional polymorphism of the MMP-1 promoter (-1607 1G/2G) in potentially malignant and malignant head and neck lesions in an Indian population. Biomarkers, 15, 684-92. crossref(new window)

6.
Chaudhary AK, Pandya S, Mehrotra R, et al (2011). Role of functional polymorphism of matrix metalloproteinase-2 (-1306 C/T and -168 G/T) and MMP-9 (-1562 C/T) promoter in oral submucous fibrosis and head and neck squamous cell carcinoma in an Indian population. Biomarkers, 16, 577-86. crossref(new window)

7.
Chaudhary AK, Singh M, Bharti AC, et al (2010b). Genetic polymorphisms of matrix metalloproteinases and their inhibitors in potentially malignant and malignant lesions of the head and neck. J Biomed Sci, 17, 10. crossref(new window)

8.
Dakshinamurthy AG, Novitzky N, Bharadwaj R, et al (2005). Cytogenetic analysis of 52 Indian patients with de novo myelodysplastic syndromes-a comparative analysis of results with reports from Asia. Ann Hematol, 84, 298-303. crossref(new window)

9.
de Souza Fernandez T, Ornellas MH, Otero de Carvalho L, et al (2000). Chromosomal alterations associated with evolution from myelodysplastic syndrome to acute myeloid leukemia. Leuk Res, 24, 839-48. crossref(new window)

10.
Diao LP, Ma H, Wei GC, et al (2012). Matrix metalloproteinase-2 promoter and tissue inhibitor of metalloproteinase-2 gene polymorphisms in non-Hodgkin's lymphoma. Int J Cancer, 131, 1095-103. crossref(new window)

11.
Egeblad M, Werb Z (2002). New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer, 2, 161-74. crossref(new window)

12.
Galm O, Suzuki H, Akiyama Y, et al (2005). Inactivation of the tissue inhibitor of metalloproteinases-2 gene by promoter hypermethylation in lymphoid malignancies. Oncogene, 24, 4799-805. crossref(new window)

13.
Gao H, Peng C, Liang B, et al (2014). beta6 integrin induces the expression of metalloproteinase-3 and metalloproteinase-9 in colon cancer cells via ERK-ETS1 pathway. Cancer Lett, 354, 427-37. crossref(new window)

14.
Gouda HM, Khorshied MM, El Sissy MH, et al (2014). Association between matrix metalloproteinase 2 (MMP2) promoter polymorphisms and the susceptibility to non-Hodgkin's lymphoma in Egyptians. Ann Hematol, 93, 1313-8.

15.
Heissig B, Hattori K, Dias S, et al (2002). Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell, 109, 625-37. crossref(new window)

16.
Hwang TL, Changchien TT, Wang CC, et al (2014). Claudin-4 expression in gastric cancer cells enhances the invasion and is associated with the increased level of matrix metalloproteinase-2 and -9 expression. Oncol Lett, 8, 1367-71.

17.
Ishihara M, Nishida C, Tashiro Y, et al (2012). Plasmin inhibitor reduces T-cell lymphoid tumor growth by suppressing matrix metalloproteinase-9-dependent CD11b(+)/F4/80(+) myeloid cell recruitment. Leukemia, 26, 332-9. crossref(new window)

18.
Issa A, Le TX, Shoushtari AN, et al (2009). Vascular endothelial growth factor-C and C-C chemokine receptor 7 in tumor cell-lymphatic cross-talk promote invasive phenotype. Cancer Res, 69, 349-57. crossref(new window)

19.
Issa JP (2013). The myelodysplastic syndrome as a prototypical epigenetic disease. Blood, 121, 3811-7. crossref(new window)

20.
Janowska-Wieczorek A, Majka M, Marquez-Curtis L, et al (2002). Bcr-abl-positive cells secrete angiogenic factors including matrix metalloproteinases and stimulate angiogenesis in vivo in Matrigel implants. Leukemia, 16, 1160-6. crossref(new window)

21.
Kalluri R (2003). Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer, 3, 422-33. crossref(new window)

22.
Klepin HD, Rao AV, Pardee TS (2014). Acute myeloid leukemia and myelodysplastic syndromes in older adults. J Clin Oncol.

23.
Kossakowska AE, Edwards DR, Prusinkiewicz C, et al (1999). Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) expression in malignant non-Hodgkin's lymphomas. Blood, 94, 2080-9.

24.
Langers AM, Verspaget HW, Hawinkels LJ, et al (2012). MMP-2 and MMP-9 in normal mucosa are independently associated with outcome of colorectal cancer patients. Br J Cancer, 106, 1495-8. crossref(new window)

25.
Lin LI, Lin DT, Chang CJ, et al (2002). Marrow matrix metalloproteinases (MMPs) and tissue inhibitors of MMP in acute leukaemia: potential role of MMP-9 as a surrogate marker to monitor leukaemic status in patients with acute myelogenous leukaemia. Br J Haematol, 117, 835-41. crossref(new window)

26.
Lin SC, Chung MY, Huang JW, et al (2004). Correlation between functional genotypes in the matrix metalloproteinases-1 promoter and risk of oral squamous cell carcinomas. J Oral Pathol Med, 33, 323-6. crossref(new window)

27.
Marquez-Curtis LA, Dobrowsky A, Montano J, et al (2001). Matrix metalloproteinase and tissue inhibitors of metalloproteinase secretion by haematopoietic and stromal precursors and their production in normal and leukaemic long-term marrow cultures. Br J Haematol, 115, 595-604. crossref(new window)

28.
Ogawa M, Kawamoto M, Yamanaka N (2000). Matrix metalloproteinase and tissue inhibitor of metalloproteinase in human bone marrow tissues-an immunohistochemical study. J Nippon Med Sch, 67, 235-41. crossref(new window)

29.
Redondo-Munoz J, Ugarte-Berzal E, Terol MJ, et al (2010). Matrix metalloproteinase-9 promotes chronic lymphocytic leukemia b cell survival through its hemopexin domain. Cancer Cell, 17, 160-72. crossref(new window)

30.
Ries C, Loher F, Zang C, et al (1999). Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes. Clin Cancer Res, 5, 1115-24.

31.
Rollison DE, Howlader N, Smith MT, et al (2008). Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood, 112, 45-52. crossref(new window)

32.
Roy R, Zurakowski D, Wischhusen J, et al (2014). Urinary TIMP-1 and MMP-2 levels detect the presence of pancreatic malignancies. Br J Cancer, 111, 1772-9. crossref(new window)

33.
S VANN, Skarstedt M, Lofgren S, et al (2013). Gene polymorphism of matrix metalloproteinase-12 and -13 and association with colorectal cancer in Swedish patients. Anticancer Res, 33, 3247-50.

34.
Sawyers CL, Denny CT, Witte ON (1991). Leukemia and the disruption of normal hematopoiesis. Cell, 64, 337-50. crossref(new window)

35.
Schnerch D, Yalcintepe J, Schmidts A, et al (2012). Cell cycle control in acute myeloid leukemia. Am J Cancer Res, 2, 508-28.

36.
Stetler-Stevenson M, Mansoor A, Lim M, et al (1997). Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in reactive and neoplastic lymphoid cells. Blood, 89, 1708-15.

37.
Travaglino E, Benatti C, Malcovati L, et al (2008). Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes. Eur J Haematol, 80, 216-26. crossref(new window)

38.
Vairaktaris E, Vassiliou S, Nkenke E, et al (2008). A metalloproteinase-9 polymorphism which affects its expression is associated with increased risk for oral squamous cell carcinoma. Eur J Surg Oncol, 34, 450-5. crossref(new window)

39.
Vundinti BR, Kerketta L, Jijina F, et al (2009). Cytogenetic study of myelodysplastic syndrome from India. Indian J Med Res, 130, 155-9.

40.
Westermarck J, Kahari VM (1999). Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J, 13, 781-92.

41.
Yang X, Liu Y, Yang Y, et al (2013). Update meta-analysis on MMP-7 -181A>G polymorphism and cancer risk: evidence from 25 studies. Gene, 521, 252-8. crossref(new window)

42.
Yu Q, Stamenkovic I (2000). Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev, 14, 163-76.

43.
Zhang C, Li C, Zhu M, et al (2013). Meta-analysis of MMP2, MMP3, and MMP9 promoter polymorphisms and head and neck cancer risk. PLoS One, 8, 62023. crossref(new window)